US2005137148A1PendingUtilityA1

Compositions and methods for treating or preventing diseases of body passageways

62
Assignee: UNIV BRITISH COLUMBIAPriority: May 24, 1996Filed: Oct 22, 2004Published: Jun 23, 2005
Est. expiryMay 24, 2016(expired)· nominal 20-yr term from priority
Inventors:William L. HunterLindsay Machan
A61P 35/00A61P 31/06A61P 43/00A61P 9/10A61P 31/04A61P 9/00A61P 27/02A61K 9/12A61K 9/5153A61P 13/02A61P 11/08A61K 9/5031A61K 9/0024A61K 47/34A61P 1/04A61P 13/00A61K 31/335A61K 9/10A61K 31/00A61K 31/337A61K 9/7007A61K 9/1075A61K 31/28A61K 9/5192A61P 1/00A61P 13/08A61K 9/1647A61K 9/1635A61P 15/00A61K 9/5146A61K 9/70A61K 9/167A61P 11/00A61K 9/1652A61K 9/5138A61K 33/24
62
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention provides methods for treating or preventing diseases associated with body passageways, comprising the step of delivering to an external portion of the body passageway a therapeutic agent. Representative examples of therapeutic agents include anti-angiogenic factors, anti-proliferative agents, anti-inflammatory agents, and antibiotics.

Claims

exact text as granted — not AI-modified
1 . A method for treating an infectious disease associated with narrowing or obstruction of a body passageway, comprising delivering to an external portion of the body passageway of a patient in need thereof a therapeutically effective amount of an antibiotic or a composition comprising an antibiotic, such that the infectious disease is treated.  
     
     
         2 . The method of  claim 1  wherein the infectious disease is a male reproductive tract disease.  
     
     
         3 . The method of  claim 2  wherein the male reproductive tract disease is urethritis, epididymitis, or prostatitis.  
     
     
         4 . The method of  claim 1  wherein the infectious disease is a female reproductive tract disease.  
     
     
         5 . The method of  claim 4  wherein the disease is vaginitis, cervicitis, or a pelvic inflammatory disease (PID).  
     
     
         6 . The method of  claim 5  wherein the PID is tuberculosis, gonococcus, chlamydia, enterococcus, or syphilis.  
     
     
         7 . The method of  claim 1  wherein the infectious disease is a urinary tract disease.  
     
     
         8 . The method of  claim 7  wherein the urinary tract disease is cystitis or urethritis.  
     
     
         9 . The method of  claim 1  wherein the infectious disease is a disease of the respiratory tract.  
     
     
         10 . The method of  claim 1  wherein the infectious disease is an anaerobic infection, fungal infection, parasitic infection, or mycobacteria infection.  
     
     
         11 . The method of  claim 1  wherein the infectious disease is chronic bronchitis or tuberculosis.  
     
     
         12 . The method of  claim 1  wherein the infectious disease is a cardiovascular disease.  
     
     
         13 . The method of  claim 12  wherein the cardiovascular disease is mycotic aneurysm or infective endocarditis.  
     
     
         14 . The method of  claim 1  wherein the body passageway is selected from the group consisting of arteries, veins, and capillaries.  
     
     
         15 . The method of  claim 1  wherein the body passageway is selected from the group consisting of lacrimal ducts, trachea, bronchi, bronchiole, nasal airways, sinus passages, eustachian tubes, and an external auditory canal.  
     
     
         16 . The method of  claim 1  wherein the body passageway is selected from the group consisting of an esophagus, a stomach, a duodenum, a small intestine, a large intestine, biliary tracts, a ureter, a bladder, a urethra, fallopian tubes, a uterus, a vagina, and a vas deferens.  
     
     
         17 . The method of  claim 1  wherein the antibiotic is an antibacterial agent.  
     
     
         18 . The method of  claim 1  wherein the antibiotic is an antimicrobial agent.  
     
     
         19 . The method of  claim 1  wherein the antibiotic is an antiviral agent.  
     
     
         20 . The method of  claim 1  wherein the antibiotic is an antiprotozoal agent.  
     
     
         21 . The method of  claim 1  wherein the antibiotic is an antifungal agent.  
     
     
         22 . The method of  claim 1  wherein the antibiotic is a macrolide antibiotic.  
     
     
         23 . The method of  claim 1  wherein the antibiotic is doxorubicin.  
     
     
         24 . The method of  claim 1  wherein the composition is biodegradable.  
     
     
         25 . The method of  claim 1  wherein the composition is non-biodegradable.  
     
     
         26 . The method of  claim 1  wherein the composition further comprises a polymer.  
     
     
         27 . The method of  claim 26  wherein the polymer is biodegradable.  
     
     
         28 . The method of  claim 26  wherein the polymer is non-biodegradable.  
     
     
         29 . The method of  claim 1  wherein the composition further comprises a copolymer of lactic acid and glycolic acid.  
     
     
         30 . The method of  claim 1  wherein the composition further comprises a poly(caprolactone).  
     
     
         31 . The method of  claim 1  wherein the composition further comprises a poly(lactic acid).  
     
     
         32 . The method of  claim 1  wherein the composition further comprises a copolymer of poly(lactic acid) and poly(caprolactone).  
     
     
         33 . The method of  claim 1  wherein the composition further comprises a poly(ethylene-vinyl acetate).  
     
     
         34 . The method of  claim 1  wherein the composition further comprises a polyester.  
     
     
         35 . The method of  claim 1  wherein the composition further comprises a polyurethane.  
     
     
         36 . The method of  claim 1  wherein the composition further comprises a polyanhydride.  
     
     
         37 . The method of  claim 1  wherein the composition further comprises a gelatin.  
     
     
         38 . The method of  claim 1  wherein the composition is in the form of a paste.  
     
     
         39 . The method of  claim 1  wherein the composition is in the form of a film.  
     
     
         40 . The method of  claim 1  wherein the composition is in the form of a spray.  
     
     
         41 . The method of  claim 1  wherein the composition comprises microspheres having an average size ranging from about 0.5 μm to 200 μm.  
     
     
         42 . The method of  claim 1  wherein the antibiotic or the composition comprising the antibiotic is administered percutaneously to the exterior surface of the body passageway.  
     
     
         43 . The method of  claim 1  wherein the antibiotic or the composition comprising the antibiotic is applied to the adventitial surface of the body passageway.  
     
     
         44 . A method for treating or preventing an infectious disease associated with narrowing or obstruction of a body passageway, comprising delivering to smooth muscle cells via the adventitia of the body passageway of a patient in need thereof a therapeutically effective amount of an antibiotic or a composition comprising an antibiotic, such that the infectious disease is treated.  
     
     
         45 . The method of  claim 44  wherein the infectious disease is a male reproductive tract disease.  
     
     
         46 . The method of  claim 45  wherein the male reproductive tract disease is urethritis, epididymitis, or prostatitis.  
     
     
         47 . The method of  claim 44  wherein the infectious disease is a female reproductive tract disease.  
     
     
         48 . The method of  claim 47  wherein the disease is vaginitis, cervicitis, or a pelvic inflammatory disease (PID).  
     
     
         49 . The method of  claim 48  wherein the PID is tuberculosis, gonococcus, chlamydia, enterococcus, or syphilis.  
     
     
         50 . The method of  claim 44  wherein the infectious disease is a urinary tract disease.  
     
     
         51 . The method of  claim 50  wherein the urinary tract disease is cystitis or urethritis.  
     
     
         52 . The method of  claim 44  wherein the infectious disease is a disease of the respiratory tract.  
     
     
         53 . The method of  claim 44  wherein the infectious disease is an anaerobic infection, fungal infection, parasitic infection, or mycobacteria infection.  
     
     
         54 . The method of  claim 44  wherein the infectious disease is chronic bronchitis or tuberculosis.  
     
     
         55 . The method of  claim 44  wherein the infectious disease is a cardiovascular disease.  
     
     
         56 . The method of  claim 55  wherein the cardiovascular disease is mycotic aneurysm or infective endocarditis.  
     
     
         57 . The method of  claim 44  wherein the body passageway is selected from the group consisting of arteries, veins, and capillaries.  
     
     
         58 . The method of  claim 44  wherein the body passageway is selected from the group consisting of lacrimal ducts, trachea, bronchi, bronchiole, nasal airways, sinus passages, eustachian tubes, and an external auditory canal.  
     
     
         59 . The method of  claim 44  wherein the body passageway is selected from the group consisting of an esophagus, a stomach, a duodenum, a small intestine, a large intestine, biliary tracts, a ureter, a bladder, a urethra, fallopian tubes, a uterus, a vagina, and a vas deferens.  
     
     
         60 . The method of  claim 44  wherein the antibiotic is an antibacterial agent.  
     
     
         61 . The method of  claim 44  wherein the antibiotic is an antimicrobial agent.  
     
     
         62 . The method of  claim 44  wherein the antibiotic is an antiviral agent.  
     
     
         63 . The method of  claim 44  wherein the antibiotic is an antiprotozoal agent.  
     
     
         64 . The method of  claim 44  wherein the antibiotic is an antifungal agent.  
     
     
         65 . The method of  claim 44  wherein the antibiotic is a macrolide antibiotic.  
     
     
         66 . The method of  claim 44  wherein the antibiotic is doxorubicin.  
     
     
         67 . The method of  claim 44  wherein the composition is biodegradable.  
     
     
         68 . The method of  claim 44  wherein the composition is non-biodegradable.  
     
     
         69 . The method of  claim 44  wherein the composition further comprises a polymer.  
     
     
         70 . The method of  claim 69  wherein the polymer is biodegradable.  
     
     
         71 . The method of  claim 69  wherein the polymer is non-biodegradable.  
     
     
         72 . The method of  claim 44  wherein the composition further comprises a copolymer of lactic acid and glycolic acid.  
     
     
         73 . The method of  claim 44  wherein the composition further comprises a poly(caprolactone).  
     
     
         74 . The method of  claim 44  wherein the composition further comprises a poly(lactic acid).  
     
     
         75 . The method of  claim 44  wherein the composition further comprises a copolymer of poly(lactic acid) and poly(caprolactone).  
     
     
         76 . The method of  claim 44  wherein the composition further comprises a poly(ethylene-vinyl acetate).  
     
     
         77 . The method of  claim 44  wherein the composition further comprises a polyester.  
     
     
         78 . The method of  claim 44  wherein the composition further comprises a polyurethane.  
     
     
         79 . The method of  claim 44  wherein the composition further comprises a polyanhydride.  
     
     
         80 . The method of  claim 44  wherein the composition further comprises a gelatin.  
     
     
         81 . The method of  claim 44  wherein the composition is in the form of a paste.  
     
     
         82 . The method of  claim 44  wherein the composition is in the form of a film.  
     
     
         83 . The method of  claim 44  wherein the composition is in the form of a spray.  
     
     
         84 . The method of  claim 44  wherein the composition comprises microspheres having an average size ranging from about 0.5 μm to 200 μm.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.